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Changes in epidermal growth factor receptor expression and response to
ligand associated with acquired tamoxifen resistance or oestrogen
independence in the ZR-75-1 human breast cancer cell line
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Summary We have examined the expression of receptors for epidermal growth factor (EGFR) by the
ZR-75-1 human breast cancer cell line and tamoxifen resistant (ZR-75-9al 8pM) and oestrogen independent/
tamoxifen sensitive (ZR-PR-LT) variants. The parent line expressed a single class of high affinity binding sites
(4,340±460 receptors/cell; Kd 0.23 +0.04 nM). ZR-75-9a1 8 lM cells, routinely maintained in medium contain-
ing 8 ILM tamoxifen, were negative for oestrogen receptor (ER) and progesterone receptor (PGR) and
expressed a markedly increased number of EGFR (14,723±2116 receptors/cell). Receptor affinity was
unchanged. Time dependent reversal of the tamoxifen resistant phenotype was accompanied by a return to ER
and PGR positivity and a fall in EGFR numbers to parent cell levels. In contrast ZR-PR-LT cells had a
greatly reduced EGFR content (803 ± 161 receptors/cell) accompanying elevated PGR numbers. Pre-treatment
of these cells with suramin or mild acid stripping failed to expose receptors which may have been occupied by
endogenously produced ligand. Increased proliferation of ZR-75-1 cells treated with EGFR (0.01-10 ng ml ')
was only observed in serum-free medium lacking insulin and oestradiol. Under these conditions untreated cells
failed to proliferate. Both variant lines continued to proliferate in serum free medium in the absence or
prescence of insulin and oestradiol but failed to respond to exogenous EGF.
It is now well established that breast cancer cell proliferation
is influenced by several peptide growth factors acting in an
autocrine or paracrine fashion. A number of studies have
suggested that oestradiol may exert its growth promoting
effect in part by stimulating the secretion of mitogenic pep-
tides such as transforming growth factor (TGF) a (Dickson
et al., 1986) and reducing the production of the inhibitory
peptide TGFP (Knabbe et al., 1987) whilst oestrogen inde-
pendent breast tumours produce growth stimulatory peptides
constitutively (Lippman et al., 1987). TGFa functions
through interaction with the epidermal growth factor recep-
tor [EGFR] (Derynck, 1988) and EGF itself is also a potent
mitogen for breast cancer.
EGFR is the cellular homologue of the product of the
c-erbB oncogene and its presence in primary breast tumours
is a strong prognostic factor. Patients presenting with
tumours positive for EGFR tend to be oestrogen receptor
(ER) negative and have an increased risk of early recurrence
and death (Sainsbury et al., 1987). Such patients are also at
risk of rapid disease progression in the face of antioestrogen
therapy (Nicholson et al., 1988a). Whilst it may be postu-
lated that elevated EGFR expression may sensitise cells to
the mitogenic effects of EGF and/or TGFx there is a poor
correlation between EGFR levels and response to EGF. Cell
lines in vitro expressing high EGFR numbers are generally
growth inhibited by EGF (Barnes, 1982; Filmus et al., 1985)
and it has been suggested that EGFR may be upregulated by
agents such as progestins which are in themselves growth
inhibitory (Murphy et al., 1985). Elucidation of the relation-
ship between EGFR expression by breast carcinoma cells in
vitro and response to EGF/TGFa is further complicated by
the marked influence of culture conditions on response
(Osborne et al., 1980; Nelson et al., 1989). In this study we
have determined expression of EGFR by the oestrogen res-
ponsive human breast cancer cell line ZR-75-1 and two
variant lines developed in our laboratory. The ZR-75-9al line
was selected for anti-oestrogen resistance by prolonged cul-
ture in the presence of increasing concentrations of tamoxifen
(van den Berg et al., 1989). An oestrogen independent/tamo-
xifen sensitive line ZR-PR-LT was isolated by continued
maintenance in medium lacking known oestrogenic activity
(van den Berg et al., 1990). Both of these variant lines have a
markedly different steroid hormone receptor profile com-
pared to the parent line and we show in this study that there
are also marked differences in EGFR expression and res-
ponse to exogenous EGF.
Materials and methods
Cell lines
The ZR-75-1 human breast cancer cell line was obtained
from Flow Laboratories, Irvine, Scotland. Cells were routine-
ly maintained in RPMI 1640 medium supplemented with 5%
foetal calf serum (FCS, Imperial Laboratories, Andover,
Hampshire), 100 IU ml-' penicillin and 1001g ml-' strepto-
mycin.
Tamoxifen resistant ZR-75-9al cells were maintained in
the same medium supplemented with 8ytM tamoxifen (van
den Berg et al., 1989). ZR-75-9al cells maintained in the
presence of tamoxifen are referred to as ZR-75-9al 8 tLM. For
certain experiments ZR-75-9al cells were transferred for
varying periods of time to drug-free RPMI 1640 medium
lacking phenol red and supplemented with heat treated and
dextran coated charcoal-stripped 5% FCS (FCSdcc). Oestro-
gen independent ZR-PR-LT cells were selected and main-
tained in this oestrogen-free medium. This variant line fails
to express binding sites characteristic of the Type 1 ER, is
not growth stimulated by oestrogen but expresses elevated
levels of progesterone receptor [PGR] (van den Berg et al.,
1990). Neither variant line is clonal in origin (van den Berg et
al., 1989; van den Berg et al., 1990).
Drugs and chemicals
Tamoxifen, bovine insulin, transferrin, dexamethasone, L-
Tri-Todothyronine, bovine plasma fibronectin, bovine serum
albumin and 17-P oestradiol were obtained from the Sigma
Chemical Co., Poole, Dorset. Murine receptor grade EGF
was purchased from ICN, Cleveland, Ohio, 125I NaI (Specific
Activity 37 GBq ml-') was obtained from Amersham Inter-
national and lodogen from the Pierce Chemical Co., Illinois.
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Suramin was a gift from Dr R. Clarke, Lombardi Cancer
Research Centre, Georgetown University Medical Center,
Washington DC.
Serumfree medium
'Complete' serum free medium (SFM) consisted of RPMI
1640 medium lacking phenol red and supplemented with
transferrin (1 jg ml1), L-Tri-Iodothyronine (108M), Fibro-
nectin (100 ngml'), Dexamethasone (10-8M), Insulin (5 x
10-7M) and oestradiol (10-8M). Cell proliferative capacity
and response to EGF was also assessed on cells growing in
SFM lacking insulin or oestradiol.
Radioiodination ofEGF
EGF was radioiodinated using the lodogen method (Fraker
& Speck, 1978). EGF (10fg) in 100 ll of 0.2 M sodium
phosphate buffer, pH 7.4, was added to an Iodogenr (41ig)
coated tube followed by 37 MBq NaT'25. The reaction pro-
ceeded for 20 min at 25°C and the mixture fractionated
by reverse-phase high-performance liquid chromatography
(HPLC) using a Waters Associates (Milford) gradient system
fitted with an analytical it-Bondapak C18 column. The elut-
ing gradient was Trifluoroacetic acid [TFA]/Water (0.05%/
99.5% v/v) to TFA/Water/Acetonitrile (0.05/29.95/70.0 v/v)
at a flow rate of 1.5 ml min-. The column eluent was
monitored at 214 nm (AUFS 0.2) and fractions were collect-
ed every 30s (0.75 ml). Twenty-five tlI aliquots from each
fraction were taken for monitoring of radioactivity and peak
fractions were pooled and stored in aliquots containing 4%
FCS. The specific activity of 1251 EGF prepared on five
occasions using this method ranged from
15.3-19.1 TBqmmol-'.
Receptor assays
Oestrogen receptor (ER) and progesterone receptor (PGR)
expression was determined using a whole cell binding assay
at 37°C as previously described (van den Berg et al., 1987).
For EGFR assays cells (2 x 105) were plated into 24 place
multiwell dishes. Cells were allowed to attach for either 24 or
48 h in drug-free medium and 1251 EGF binding was then
assessed at 4°C. Medium was replaced with RPMI medium
(0.5 ml) supplemented with 1% bovine serum albumin con-
taining 1251I EGF (0.2-4 nM) in the absence or presence of a
100-fold excess of non-labelled EGF to determine non-
specific binding. Following a 1 h incubation period medium
was removed and wells were rinsed twice with ice-cold PBS.
1 M NaOH (500JLl) was added to each well and plates were
incubated for 1 h at 37°C to extract radioactivity. Extracts
were removed by aspiration and wells were washed once with
the same volume of alkali. Washings were added to the
appropriate tubes and radioactivity determined by gamma
counting (NEN 1600) or scintillation counting (LKB Wallac
1410 LSC). Since it has been shown that pretreatment ofcells
with the polyanionic drug suramin can reveal EGFR occup-
ied by endogenously produced TGFax (Coffey et al., 1987;
Clarke et al., 1989) in certain experiments ZR-PR-LT cells
were exposed to suramin (1 mg ml 1) for 24 h prior to EGFR
measurement. As an alternative method, PBS rinsed cells
were subjected to mild acid stripping (2 x 3 min treatments
with 1 ml 0.05 M sodium acetate buffer, pH 4.5, containing
150 mM NaCl) prior to EGFR assay.
Maximum binding capacity (Bmax) and affinity (Kd) were
calculated by Woolf analysis after linearisation of specific
binding data (Keightly & Cressie, 1980).
Effects ofEGFon cellproliferation
Cells (5 x 104 per well) were plated into 24 place multiwell
dishes in routine growth medium. After a 24 h attachment
period medium was replaced with medium containing EGF
(0.01-10ngml-') and cells were counted at 0, 6 and 9 days
during continuous treatment using a Coulter Counter Model
D. In experiments to determine the effect of EGF on cell
proliferation in SFM, plating medium was replaced with
SFM or SFM lacking insulin and oestradiol and cells allowed
to adapt to growth under these conditions for 2 days before
exposing them to EGF.
Results
Table I shows the ER and PGR status of ZR-75-1, ZR-75-
9al and ZR-PR-LT cells. The parent line is ER positive and
responds to oestradiol with a marked increase in PGR ex-
pression. As previously reported (van den Berg et al., 1989)
ZR-75-9al cells routinely maintained in the presence of 8 t4M
tamoxifen are ER and PGR negative. We have previously
reported that the tamoxifen resistant phenotype of ZR-75-
9al cells is rapidly reversed when the cells are maintained in
drug-free RPMI supplemented with 5% FCS whilst the resis-
tant phenotype is maintained for at least 12 weeks under
drug and oestrogen-free culture conditions (van den Berg et
al., 1989). Table I indicates that long term culture of cells in
drug and oestrogen-free medium also results in a return to
ER and PGR positivity. ZR-PR-LT cells do not possess
specific binding sites characteristic of Type 1 ER but express
high levels of PGR which are not further induced by oestra-
diol treatment (Table I and van den Berg et al., 1990).
1251 EGF binding by ZR-75-1 cells is shown in Figure 1.
Non-specific binding was low (10-20% of total binding for
this cell line) and saturable binding was demonstrated over
the free ligand concentration used. Woolf analysis of specific
binding data (Keightly & Cressie, 1980) revealed a single
class of high affinity binding sites (Figure 1 inset). Figure 2
shows the marked differences in specific binding of 1251I EGF
to the three cell lines under investigation. Table II shows
mean values of three determinations of EGFR expression
(Bmax, expressed as receptor number per cell) and affinity of
Table I ER and PGR status ofZR-75-1 cells and variants
Cell line ER PGR basal PGR induceda
ZR-75-1 214±10 81±11 1237± 133
ZR-PR-LT ND 1675± 134 1443±215
ZR-75-9al 8tiM ND ND ND
ZR-75-9al FCSdcc 447±37 87± 19 1474± 193
a5dayexposureto 17, oestradiol(10-I M). Allvaluesareexpressed as
fmol mg-' protein and are means and standard errors of three
determinations. ND = not detectable. ZR-75-9al 8glM cells are rou-
tinelymaintainedinthepresenceof8 !LM tamoxifen. ZR-75-9al FCSdcc
cells had been maintained for 2 years in drug and phenol red free
medium supplemented with FCSdcc at the time of assay.
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Figure 1 Binding of 1251 EGFR to ZR-75-1 cells. V-V total
binding; 0-0 non-specific binding; 0-0 specific binding.
Inset: Woolf transformation of specific binding data.
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Figure 2 Specific binding of 25I EGF to ZR-75-1 (0-0),
ZR-75-9al 8fjM (0-0), and ZR-PR-LT (V-V) cells.
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Table II EGFR expression by ZR-75-1 cells and variants
Cell line Bmax (receptors/cell) Kd (nM)
ZR-75-1 4,340+460 0.23±0.04
ZR-75-9al 8lM 14,723+2116a 0.19±0.05
ZR-PR-LT 803± 161a 0.26±0.04
ZR-PR-LT + Acid wash 630±76a 0.21 ±0.06
ZR-PR-LT + Suramin 720±51a 0.31±0.09
Values aremeans and standard errors ofthree determinations except
LT-PR-LT + Acid wash or Suramin pre-treatment which are means
and s.e. oftwo determinations. ap<0.001 vs ZR-75-1 (Student t-test).
10l
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receptor for ligand (Kd) for the parent line and tamoxifen
resistant and oestrogen independent variants. It can be seen
that ZR-75-9al 8l.M cells express 2-4 times as many EGFR
as the parent line whilst in the oestrogen independent ZR-
PR-LT line EGFR numbers are markedly depressed. Neither
suramin pretreatment nor mild acid washing revealed the
presence of additional binding sites which may have been
occupied by endogenously produced ligand (Table II).
If the tamoxifen resistant line is transferred to drug and
phenol red free medium supplemented with 5% FCSdcc the
ER and PGR negative phenotype is maintained for at least
12 weeks (van den Berg et al., 1989). Table III shows that
under these culture conditions EGFR receptor expression
over a 4 week period remained elevated in comparison to
parent line values. However, ZR-75-9al cells maintained
long-term in the absence of drug or oestrogenic activity
express both ER and PGR (Table I) and are growth
inhibited by tamoxifen (data not shown). Table III shows
that EGFR expression by these cells had fallen to a value
similar to that of the parent line.
None of the cell lines under study responded to exogenous
EGF when grown under routine culture conditions (data not
shown). Figure 3 compares the proliferation of the cell lines
under these conditions with their proliferative rate in SFM
and SFM lacking insulin and oestradiol. All cell lines grew
more slowly in SFM than in the presence of FCS or FCSdcc.
Table III Time-dependentchangesin EGFRexpression byZR-75-9aI
8 JM cells following transfer to drug and phenol red-free medium
supplemented with FCSdcc
Cell line Bmax (receptors/cell) Kd (nM)
ZR-75-9al FCSdcc 1 week 8863 0.37
ZR-75-9al FCSdcc 2 weeks 8975 0.28
ZR-75-9al FCSdcc 4 weeks 13,197 0.14
ZR-75-9al FCSdcc 2 years 4240 0.18
C
0 3 6 9
Days
Figure 3 Proliferation of ZR-75-1 a, ZR-75-9al 8tIM b, and
ZR-PR-LT c, cells in serum-containing medium (0-0), SFM
(0-0), and SFM lacking insulin and oestradiol (V-V).
Values represent means± standard errors of three determinations.
In the absence of insulin and oestradiol ZR-75-1 cells failed
to proliferate whilst both ZR-75-9al 8tLM and ZR-PR-LT
cell numbers increased at a rate similar to that observed in
SFM. EGF (0.01-10 ngml-') caused a dose-dependent in-
crease in proliferative capacity of ZR-75-1 cells growing in
SFM lacking insulin or oestradiol (Figure 4). However EGF
failed to consistently influence the proliferation of ZR-75-9al
8 JLM or ZR-PR-LT cells in SFM in the absence or presence
of insulin or oestradiol (data not shown).
Discussion
All cell lines studied appeared to express a single class of
high affinity receptors for EGF (Kd 0.19-0.26 nM). These
high affinity receptors are believed to mediate the biological
effects of cognate ligands. A second class of low affinity
receptors (Kd 1-10 nM) for EGF have been described in
breast cancer cells in long term culture and in breast tumour
bipsy specimens (Clarke et al., 1989; Nicholson et al., 1988b).
Had these low affinity receptors been present in the cell lines
under study it is likely that biphasic Woolf plot would have
been generated since the ligand concentration range used
should have detected such binding sites. However we cannot
discount the possibility that a second class of binding sites
with a substantially lower affinity for EGF may be expressed
by these cells.
High affinity EGFR numbers expressed by ZR-75-1 cells in
this study (Table II) are in reasonable agreement with pre-
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Figure 4 The effect of EGF on the proliferation of ZR-75-1 cells
in SFM lacking insulin and oestradiol. * * SFM lacking
insulin and oestradiol; V V 0.01 ng ml' EGF; v V 0.1 ng
ml- EGF; 0-0 lOngml' EGF; 0 0 SFM containing
insulin (5 x Io-7 M) and 17p oestradiol (10-8 M). Values repre-
sent means ±standard errors of three determinations.
viously published data for this cell line (Davidson et al.,
1987). Both variant lines expressed markedly altered EGFR
numbers (Table II). It has been shown that patients present-
ing with breast tumours positive for EGFR tend to be ER
negative, have a poor prognosis and are resistant to tamoxi-
fen treatment (Sainsbury et al., 1987; Nicholson et al.,
1988a). This inverse relationship between EGFR and ER
expression has been confirmed using a panel of human breast
cancer cell lines (Davidson et al., 1987). Our data suggest
that acquired tamoxifen resistance as exemplified by the ZR-
75-9al 8 JiM cell line may also be associated with an increase
in EGFR numbers without a change in receptor affinity
(Figure 2 and Table II) accompanying loss of ER and PGR.
Furthermore, time dependent reversal of the tamoxifen resis-
tant phenotype is also accompanied by a fall in EGFR
numbers and a return to ER and PGR positivity (Tables I
and III). These findings add further support to the proposal
that there is an inverse relationship between EGFR and ER
expression and that a mechanism of hetero-specific receptor
modulation exists. In contrast to our results with the tamox-
ifen resistant variant, the oestrogen independent/tamoxifen
sensitive line ZR-PR-LT expresses a markedly depressed
number of EGFR. This does not seem to be the result of
partial receptor occupation or down-regulation by endogen-
ously produced ligand as suramin pre-treatment or acid
washing failed to reveal additional binding sites. The ZR-PR-
LT line is unusual in that although it appears to be negative
for Type 1 ER on ligand binding analysis it expresses very
high levels of PGR in the absence of any oestrogenic activity
(van den Berg et al., 1990 and Table I). The mechanism(s)
responsible for this phenotype remain unclear but may
involve a mutant ER lacking the ligand binding site, but
active in the absence of ligand (Graham et al., 1990) or
multiple copies of the PGR gene (Savouret et al., 1991).
Whatever the mechanism, our results with both ZR-75-9al
8 JAM and ZR-PR-LT cells suggest that there may also be an
inverse relationship between PGR expression and EGFR
content. In support of this hypothesis oestradiol, which nor-
mally induces PGR synthesis, has been reported to down-
regulate EGFR in MCF-7 cells (Berthois et al., 1989). It may
also be relevant that short term oestrogen withdrawal which
markedly reduces PGR expression (van den Berg et al., 1990)
results in elevated expression by MCF-7 and T47-D cells of
the c-erbB-2 oncogene and its encoded p185 protein, a close
EGFR homologue, whilst expression is repressed following
oestrogen treatment (Dati et al., 1990).
Our data on EGFR numbers in these variants of the
ZR-75-1 line contrast with an earlier report from this labor-
atory which showed no significant changes in expression of
receptors for Interferona 2c (Martin et al., 1991). Therefore
in this experimental model there does not appear to be close
coupling of expression of receptors for interferon a and
EGF, unlike the relationship between ER and EGFR and
PGR and EGFR. Additional studies are underway to deter-
mine whether heterospecific modulation of EGFR by inter-
ferons occurs in these cell lines, as has been previously
reported for other cell lines in vitro (Zoon et al., 1986;
Hamburger & Pinnamaneni, 1991).
The relationship between EGFR expression and prolifer-
ative response to ligand is unclear, but several studies have
suggested that elevated EGFR expression is associated with
growth inhibition rather than growth stimulation (Barnes et
al., 1982; Filmus et al., 1985) although this relationship is by
no means clear cut (Rizzino et al., 1988) and evidence has
been presented to suggest that growth inhibition in vitro may
be artifactual (Ginsburg & Vonderhaar, 1985). We have
confirmed that ZR-75-1 cells respond to EGF with growth
stimulation, but we were only able to demonstrate a consis-
tent response when cells were cultured in SFM lacking the
potent mitogens insulin and oestradiol (Figure 4). The
reasons for these findings are unclear but several studies have
demonstrated that culture conditions can markedly infuence
response to EGF (Osborne et al., 1980; Nelson et al., 1989).
It is also possible, as early studies suggested (Barnes et al.,
1982), that EGF and insulin may share a common pathway
distal to receptor-ligand interaction. In the absence of EGF
ZR-75-1 cells failed to proliferate in SFM lacking insulin and
oestradiol whilst ZR-75-9al 8 JM and ZR-PR-LT cells pro-
liferate at a rate only marginally slower than in SFM con-
taining these mitogens (Figure 3) and EGF was without
effect in the absence or presence of insulin and oestradiol.
The ability of the tamoxifen resistant and oestrogen indepen-
dent variants to proliferate in SFM lacking insulin or oestra-
diol would be consistent with the secretion by these cells of
growth factors acting in an autocrine fashion (Dickson et al.,
1986). Additional studies are underway to test this hypothesis
but the failure of ZR-PR-LT cells to express increased
EGFR numbers following suramin treatment or acid washing
(Table II) is not consistent with occupation of receptor by
TGFa. The failure of this line to respond to EGF may
therefore be simply due to the very low number of receptors
for EGF expressed. In contrast the tamoxifen resistant
variant expresses an elevated number of receptors but also
fails to respond to EGF. The reason for this is currently
unknown. Whilst a number of reports have suggested that
cell lines expressing elevated numbers of EGFR are either
growth inhibited by or fail to respond to EGF (Barnes et al.,
1982; Filmus et al., 1985; Davidson et al., 1987) these cell
lines express EGFR numbers at least one order of magnitude
higher than those reported in this study for ZR-75-9a1 8JAM
cells.
Since neither of the variant lines used in this study are
clonal in origin we are unable to say whether cells of their
phenotype were selected from the parent line population or
arose as a result of phenotypic alteration. Double labelling
immunohistochemistry experiments would be of value in
determining whether heterogeneity exists within cell popula-
tions or whether, for example, a pre-existing population of
high EGFR/low ER cells is being selected for by prolonged
tamoxifen exposure.
In summary, our results with the tamoxifen resistant line
are in agreement with those of earlier studies which have
indicated an inverse relationship between ER and EGFR
content of breast cancer cells and further indicate that
acquired tamoxifen resistance may also be associated with
elevated EGFR numbers and that reversal of the resistant
phenotype results in a fall in EGFR expression. Our data
also suggest that the acquisition of oestrogen insensitivity
associated with elevated PGR expression, as exemplified by
ZR-PR-LT cells, may have opposite effects on EGFR
numbers. Further studies will be required to test the genera-
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lity of our findings but these and earlier studies indicate that
there is a complex relationship between expression of recep-
tors for factors influencing the proliferation of breast cancer
cells, response to those factors and their role in the develop-
ment of hormonal independence.
This study was supported by the Dr Hadwen Trust for Humane
Research and the Ulster Cancer Foundation.
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